Evaluation of HOXA5 methylation–gene expression in response to Imatinib mesylate treatment in chronic myeloid leukemia
نویسندگان
چکیده
Introduction and Aim: Genetic epigenetic factors affect chronic myeloid leukemia (CML) treatment response. This study aimed to investigate HOXA5 methylation gene expression with Imatinib mesylate (IM) response in CML patients assess their predictive value as markers. Materials Methods: Blood samples were collected from 50 (25 responders 25 non-responders mesylate) healthy controls of the same age sex. Methylation-specific quantitative PCR (MS-qPCR) was used analyze methylation, (qPCR). Results: revealed a significant higher level demethylation compared control (P <0.001). Non-responder had significantly levels than responder (P<0.001 P<0.01 respectively). According optimal cut-off point determined by receiver operating characteristics (ROC) analysis, associated risk observed between (P<0.01 P<0.01, respectively) development IM resistance patients. Conclusion: can be biomarker predict
منابع مشابه
Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملDifferential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemog...
متن کاملEvaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...
متن کاملMicro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
BACKGROUND Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the e...
متن کاملMolecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. Imatinib treatment results in a high frequency o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedicine
سال: 2023
ISSN: ['2211-8020', '2211-8039']
DOI: https://doi.org/10.51248/.v43i01.2532